<\/div>![\"\"](\"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Full-Overlay-desk_d25180.png?w=1232\")
<\/picture>Drug interactions: effects of IDVYNSOTM<\/sup> (doravirine\/islatravir) on other drugs<\/h1>
<\/picture>Drug interactions: effects of IDVYNSOTM<\/sup> (doravirine\/islatravir) on other drugs<\/h1><\/p>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\nIDVYNSO is contraindicated when co-administered with: <\/strong><\/h4><\/div>\n\n\n\n\n- drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of IDVYNSO. <\/li>
- lamivudine (3TC) or emtricitabine (FTC) as significant decreases in islatravir-triphosphate (ISL-TP) concentrations may occur, which may decrease the effectiveness of IDVYNSO.<\/li><\/ul><\/div>\n\n\n\n
IDVYNSO is a complete regimen for the treatment of HIV-1 infection. It is not recommended to be administered with other HIV-1 antiretroviral medications.<\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\n\n
\n\n\n\n<\/div>\n\n\n\nBased on drug interaction studies conducted separately for doravirine and islatravir, no clinically significant drug interactions have been observed following the co-administration of those components of IDVYNSO and the following drugs:<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\nDrug interaction studies for doravirine<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\nAgents<\/strong><\/th>Doravirine<\/strong><\/th><\/tr><\/thead>islatravir<\/td> \u25cf<\/td><\/tr> dolutegravir<\/td> \u25cf<\/td><\/tr> ritonavir<\/td> \u25cf<\/td><\/tr> tenofovir disoproxil fumarate<\/td> \u25cf<\/td><\/tr> lamivudine<\/td> \u25cf<\/td><\/tr> elbasvir and grazoprevir<\/td> \u25cf<\/td><\/tr> ledipasvir and sofosbuvir<\/td> \u25cf<\/td><\/tr> ketoconazole<\/td> \u25cf<\/td><\/tr> AI(OH)3<\/sub>\/Mg(OH)2<\/sub>\/simethicone containing antacid<\/td>\u25cf<\/td><\/tr> pantoprazole<\/td> \u25cf<\/td><\/tr> atorvastatin<\/td> \u25cf<\/td><\/tr> an oral contraceptive containing ethinyl estradiol and levonorgestrel<\/td> \u25cf<\/td><\/tr> metformin<\/td> \u25cf<\/td><\/tr> methadone<\/td> \u25cf<\/td><\/tr><\/tbody> midazolam<\/td> \u25cf<\/td><\/tr><\/tfoot><\/table><\/figure>\n<\/div>\n\n\n\n
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n\nIDVYNSO is contraindicated when co-administered with: <\/strong><\/h4><\/div>\n\n\n\n\n
IDVYNSO is contraindicated when co-administered with: <\/strong><\/h4><\/div>\n\n\n\n\n- drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of IDVYNSO. <\/li>
- lamivudine (3TC) or emtricitabine (FTC) as significant decreases in islatravir-triphosphate (ISL-TP) concentrations may occur, which may decrease the effectiveness of IDVYNSO.<\/li><\/ul><\/div>\n\n\n\n
IDVYNSO is a complete regimen for the treatment of HIV-1 infection. It is not recommended to be administered with other HIV-1 antiretroviral medications.<\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\n\n
\n\n\n\n<\/div>\n\n\n\nBased on drug interaction studies conducted separately for doravirine and islatravir, no clinically significant drug interactions have been observed following the co-administration of those components of IDVYNSO and the following drugs:<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\nDrug interaction studies for doravirine<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\nAgents<\/strong><\/th>Doravirine<\/strong><\/th><\/tr><\/thead>islatravir<\/td> \u25cf<\/td><\/tr> dolutegravir<\/td> \u25cf<\/td><\/tr> ritonavir<\/td> \u25cf<\/td><\/tr> tenofovir disoproxil fumarate<\/td> \u25cf<\/td><\/tr> lamivudine<\/td> \u25cf<\/td><\/tr> elbasvir and grazoprevir<\/td> \u25cf<\/td><\/tr> ledipasvir and sofosbuvir<\/td> \u25cf<\/td><\/tr> ketoconazole<\/td> \u25cf<\/td><\/tr> AI(OH)3<\/sub>\/Mg(OH)2<\/sub>\/simethicone containing antacid<\/td>\u25cf<\/td><\/tr> pantoprazole<\/td> \u25cf<\/td><\/tr> atorvastatin<\/td> \u25cf<\/td><\/tr> an oral contraceptive containing ethinyl estradiol and levonorgestrel<\/td> \u25cf<\/td><\/tr> metformin<\/td> \u25cf<\/td><\/tr> methadone<\/td> \u25cf<\/td><\/tr><\/tbody> midazolam<\/td> \u25cf<\/td><\/tr><\/tfoot><\/table><\/figure>\n<\/div>\n\n\n\n
- drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of IDVYNSO. <\/li>
- lamivudine (3TC) or emtricitabine (FTC) as significant decreases in islatravir-triphosphate (ISL-TP) concentrations may occur, which may decrease the effectiveness of IDVYNSO.<\/li><\/ul><\/div>\n\n\n\n
IDVYNSO is a complete regimen for the treatment of HIV-1 infection. It is not recommended to be administered with other HIV-1 antiretroviral medications.<\/strong><\/h4><\/div>\n\n\n\n
<\/div>\n\n\n\n\n
\n\n\n\n<\/div>\n\n\n\nBased on drug interaction studies conducted separately for doravirine and islatravir, no clinically significant drug interactions have been observed following the co-administration of those components of IDVYNSO and the following drugs:<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n\n\nDrug interaction studies for doravirine<\/strong><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\nAgents<\/strong><\/th> Doravirine<\/strong><\/th><\/tr><\/thead> islatravir<\/td> \u25cf<\/td><\/tr> dolutegravir<\/td> \u25cf<\/td><\/tr> ritonavir<\/td> \u25cf<\/td><\/tr> tenofovir disoproxil fumarate<\/td> \u25cf<\/td><\/tr> lamivudine<\/td> \u25cf<\/td><\/tr> elbasvir and grazoprevir<\/td> \u25cf<\/td><\/tr> ledipasvir and sofosbuvir<\/td> \u25cf<\/td><\/tr> ketoconazole<\/td> \u25cf<\/td><\/tr> AI(OH)3<\/sub>\/Mg(OH)2<\/sub>\/simethicone containing antacid<\/td> \u25cf<\/td><\/tr> pantoprazole<\/td> \u25cf<\/td><\/tr> atorvastatin<\/td> \u25cf<\/td><\/tr> an oral contraceptive containing ethinyl estradiol and levonorgestrel<\/td> \u25cf<\/td><\/tr> metformin<\/td> \u25cf<\/td><\/tr> methadone<\/td> \u25cf<\/td><\/tr><\/tbody> midazolam<\/td> \u25cf<\/td><\/tr><\/tfoot><\/table><\/figure>\n<\/div>\n\n\n\n
![\"\"](\"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Group-268@2x.png\" "\\"Group-268@2x\\"")
![\"\"](\"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/DDI_Callout12_Mobile.svg\" "\\"DDI_Callout1+2_Mobile\\"")
<\/figure><\/div><\/div>\n\n\n\n